<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04220190</url>
  </required_header>
  <id_info>
    <org_study_id>RAPA-501-ALS</org_study_id>
    <nct_id>NCT04220190</nct_id>
  </id_info>
  <brief_title>RAPA-501 Therapy for ALS</brief_title>
  <official_title>Phase I Trial of Autologous Hybrid TREG/Th2 Cell (RAPA-501) Therapy for Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rapa Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hackensack Meridian Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rapa Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RAPA-501-ALS is an open-label, dose escalation, Phase 1/2 study of RAPA-501 autologous T&#xD;
      cells in adults with amyotrophic lateral sclerosis (ALS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, non-randomized, multi-center Phase 1/2 study evaluating RAPA-501 T&#xD;
      cells in subjects with amyotrophic lateral sclerosis.&#xD;
&#xD;
      After a subject consents to the study, an apheresis procedure will be performed to collect&#xD;
      cells to manufacture the investigational product, RAPA-501 T cells.&#xD;
&#xD;
      This study consists of three cohorts. Cohorts 1 and 2 will evaluate a 6-month regimen of four&#xD;
      (4) cycles of RAPA-501 T cell therapy without the pentostatin-cyclophosphamide host&#xD;
      conditioning regimen (PC regimen). Cohorts 1 and 2 will evaluate two different doses: Cohort&#xD;
      1 - 40 x 10^6 cells/infusion and Cohort 2 - 160 x 10^6 cells/infusion. Both cohorts will&#xD;
      evaluate a 6-month regimen of four cycles of the RAPA-501 cell therapy.&#xD;
&#xD;
      Cohort 3 will evaluate the highest safe dose of RAPA-501 cells (from Cohort 1 and Cohort 2)&#xD;
      in combination with the PC regimen. Cohort 3 will evaluate a 6-month regimen of 4 cycles of&#xD;
      RAPA-501 cells administered after the PC regimen. The PC regimen will be 7 days in duration&#xD;
      and the RAPA-501 cell therapy will take place on Day 8.&#xD;
&#xD;
      All subjects who complete active treatment on each cohort will then complete the follow-up&#xD;
      portion of the study (approximately 6-months in duration).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Dose safety of single-agent RAPA-501 T cells</measure>
    <time_frame>30 days after the first infusion of RAPA-501 T cells.</time_frame>
    <description>To determine the safety of single-agent RAPA-501 T cells administered intravenously (i.v.) at dose level 1 and dose level 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Highest tolerated dose of RAPA-501 T cells</measure>
    <time_frame>30 days after the first infusion of RAPA-501 T cells.</time_frame>
    <description>Determine the safety of the highest tolerated dose of RAPA-501 T cells in combination with pentostatin and cyclophosphamide host conditioning (PC regimen).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of therapy on disease status</measure>
    <time_frame>One year after treatment initiation.</time_frame>
    <description>To determine the ALS disease activity score (Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised and Rasch Overall ALS Disability Scale [ROADS]) for each study cohort pre-therapy, during study interventions, and after the post-therapy observation interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize immune system parameters</measure>
    <time_frame>One year after treatment initiation.</time_frame>
    <description>Determine whether therapy increases the number of circulating Th2 and TREG cells, as measured by T cells that express the transcription factors GATA3 and FOXP3 by flow cytometry, respectively. The absolute number of GATA3+ and FOXP3+ T cells will be determined pre- and post-therapy (unit of measurement for both GATA3 and FOP3: absolute number of positive cells per microliter of blood).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize immune system parameters</measure>
    <time_frame>One year after treatment initiation.</time_frame>
    <description>Determine whether therapy reduces the number of circulating Th1 cells, as measured by T cells that express the transcription factor TBET by flow cytometry, respectively. The absolute number of TBET+ cells will be determined pre- and post-therapy (unit of measure for TBET: number of positive cells per microliter of blood).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize pulmonary function test parameters</measure>
    <time_frame>One year after treatment initiation.</time_frame>
    <description>Determine whether therapy increases pulmonary function, as determined by measurement of pre- and post-therapy measures of Slow Vital Capacity (SVC) (unit of measurement: percent of age-predicted value).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize hand grip strength</measure>
    <time_frame>One year after treatment initiation.</time_frame>
    <description>Characterize hand grip strength pre- and post-therapy using hand-held dynamometry.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cerebrospinal fluid assessment</measure>
    <time_frame>Six months after treatment initiation.</time_frame>
    <description>To assess cerebrospinal fluid pre- and post- therapy for content of inflammation molecules and neurodegeneration molecules.</description>
  </other_outcome>
  <other_outcome>
    <measure>Neuroinflammation assessment</measure>
    <time_frame>Six months after treatment initiation.</time_frame>
    <description>Assess neuroinflammation in vivo using PET scan that incorporates a translocator protein radiotracer.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Single agent RAPA-501 T cells (dose level 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 1 is 40 x 10^6 cells/infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single agent RAPA-501 T cells (dose level 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 2 is 160 x 10^6 cells/infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RAPA-501 + PC Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RAPA-501 T cell therapy preceded by the pentostatin-cyclophosphamide (PC) regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RAPA-501 Autologous T cells</intervention_name>
    <description>TREG/Th2 cells</description>
    <arm_group_label>RAPA-501 + PC Regimen</arm_group_label>
    <arm_group_label>Single agent RAPA-501 T cells (dose level 1)</arm_group_label>
    <arm_group_label>Single agent RAPA-501 T cells (dose level 2)</arm_group_label>
    <other_name>RAPA-501 cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients ≥ 18 years of age.&#xD;
&#xD;
          2. Patients with sporadic or familial amyotrophic lateral sclerosis (ALS) diagnosed as&#xD;
             laboratory-supported possible, probable, or definite according to World Federation of&#xD;
             Neurology El Escorial Criteria.&#xD;
&#xD;
          3. Must have a source of autologous T cells potentially sufficient to manufacture&#xD;
             RAPA-501 cells, as defined by a peripheral CD3+ T cell count ≥ 800 cells per μl.&#xD;
&#xD;
          4. Patients may continue riluzole (Rilutek®) and/or edaravone (Radicava®) therapy if on a&#xD;
             stable dose for ≥ one month prior to study entry.&#xD;
&#xD;
          5. Patients must be ≥ two weeks from major surgery, from edaravone therapy, and from&#xD;
             participation in investigational trials.&#xD;
&#xD;
          6. Patients must have recovered from clinical toxicities (resolution of CTCAE [version 5]&#xD;
             toxicity to a value of ≤ 2).&#xD;
&#xD;
          7. Serum creatinine ≤ less than or equal to 2.0 mg/dL.&#xD;
&#xD;
          8. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x upper limit&#xD;
             of normal.&#xD;
&#xD;
          9. Bilirubin ≤ 1.5 (except if due to Gilbert's disease).&#xD;
&#xD;
         10. Pulmonary slow vital capacity (SVC) ≥ 50% of predicted normal.&#xD;
&#xD;
         11. No history of abnormal bleeding tendency.&#xD;
&#xD;
         12. Voluntary written consent must be given before performance of any study related&#xD;
             procedure not part of standard medical care, with the understanding that consent may&#xD;
             be withdrawn by the participant at any time without prejudice to future care.&#xD;
&#xD;
             For accrual to Cohort 3, additional eligibility inclusion criteria are as follows:&#xD;
&#xD;
         13. Ejection fraction by MUGA or 2-D echocardiogram within institution normal limits&#xD;
             (applies only to study participants on cohort).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active uncontrolled infection.&#xD;
&#xD;
          2. Hypertension not adequately controlled by ≤ 3 medications.&#xD;
&#xD;
          3. History of documented pulmonary embolus within 6 months of enrollment.&#xD;
&#xD;
          4. Clinically significant cardiac pathology, as defined by: myocardial infarction within&#xD;
             6 months prior to enrollment, Class III or IV heart failure according to NYHA,&#xD;
             uncontrolled angina, severe uncontrolled ventricular arrhythmias, or&#xD;
             electrocardiographic evidence of acute ischemia or active conduction system&#xD;
             abnormalities.&#xD;
&#xD;
          5. Patients with history of coronary artery bypass grafting or angioplasty will receive a&#xD;
             cardiology evaluation and be considered on a case-by-case basis.&#xD;
&#xD;
          6. HIV, hepatitis B, or hepatitis C seropositive.&#xD;
&#xD;
          7. Pregnancy or breastfeeding patients.&#xD;
&#xD;
          8. Patients of childbearing age, or males who have a partner of childbearing potential,&#xD;
             who are unwilling to practice contraception.&#xD;
&#xD;
          9. Patients may be excluded at the discretion of the PI or if it is deemed that allowing&#xD;
             participation would represent an unacceptable medical or psychiatric risk.&#xD;
&#xD;
             For accrual to Cohort 3, additional eligibility exclusion criteria are as follows:&#xD;
&#xD;
         10. Calculated creatinine clearance value of &lt; 70 mL/min/1.73 m2, as calculated by the&#xD;
             Cockcroft-Gault formula.&#xD;
&#xD;
         11. Diagnosis of malignancy (active).&#xD;
&#xD;
         12. Urinary obstruction.&#xD;
&#xD;
         13. Hypersensitivity to the agents in the PC regimen (pentostatin, cyclophosphamide).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Fowler, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Rapa Therapeutics LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Fowler Chief Medical Officer</last_name>
    <phone>3015183104</phone>
    <email>dan@rapatherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Fisher</last_name>
      <phone>617-726-9094</phone>
      <email>kefisher@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>James Berry, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Donato Principal Investigator</last_name>
      <phone>551-996-5855</phone>
      <email>michele.donato@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Michele Donato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 3, 2020</study_first_submitted>
  <study_first_submitted_qc>January 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2020</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Autologous TREG/Th2 cell therapy</keyword>
  <keyword>RAPA-501</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

